Company / Accounts Receivable
Arcutis Biotherapeutics, Inc. Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$146.2M
FY2025
5-year range
$0 / $146.2M
FY2021-FY2025
Trend
+100.1%
vs FY2024
Sector context
#39 of 115
Health Care
What the data says
At $146M, Arcutis Biotherapeutics, Inc.'s accounts receivable ranks #39 of 115 in the Health Care sector. Accounts Receivable has increased for 4 consecutive years, from $0 in FY2021 to $146M in FY2025.
Based on SEC 10-K filings.
$146M in FY2025 with a 3-year CAGR of +158.6%.
Improved from $26M to $146M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +158.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#39 of 115 in Health CareTop 34% of 115This company $146.2M Sector average $1.1B
▼
-86.9% below sector average
Key checks
Key Insights
- Arcutis Biotherapeutics, Inc.'s accounts receivable has grown for 3 consecutive years.
- 3-year CAGR of +158.6%, indicating consistent growth.
- In FY2025, accounts receivable increased 100.1% year-over-year.
- Ranks #39 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $146.2M | +100.1% |
| FY2024 | $73.1M | +183.1% |
| FY2023 | $25.8M | +205.1% |
| FY2022 | $8.5M | - |
| FY2021 | $0 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026